Xintela's stem cells show promising results in preclinical ARDS study

Lund, Sweden, 26 October 2020 - Xintela announces today that the company's selected human stem cells XSTEM® show a therapeutic effect in ARDS (Acute Respiratory Distress Syndrome) in an ongoing preclinical study in pigs. ARDS is a life-threatening lung complication that may affect severely ill covid-19 patients.

Xintela previously announced that XSTEM-ARDS is being evaluated in a well established preclinical pig model of ARDS and that Vinnova awarded a grant of SEK 1 million to fund the study. The preclinical study is being performed in collaboration with Professor Sandra Lindstedt and her team at the Cardio-thoracic surgery clinic, Skåne University Hospital in Lund and Lund University. The study involves twelve animals with the lung complication ARDS. Six animals receive intravenous treatment with XSTEM-ARDS and six control animals receive an injection without cells. During the study, various clinical parameters are monitored to measure lung and circulatory function and the health status of the animals. Blood and tissue samples are also collected and will be analyzed when the study is completed. Two animals remain to be treated before the final results can be compiled. The results so far show that XSTEM-ARDS had a positive therapeutic effect in all four animals that received stem cells. This positive effect is based on, among other things, improvement in the lungs' ability to oxygenate blood and stabilization of the blood circulatory system, compared to no improvement in the control animals, who remained in the life-threatening ARDS condition throughout the study.

"We have successfully completed the major part of the study and the results are very promising. In all animals treated with XSTEM-ARDS, we see a clear improvement in lung function and a reversal of the critical ARDS condition. For logistical reasons, it will take some time before we can complete the study, so we have chosen to report the current status and results thus far of this exciting study", says Xintela's CEO Evy Lundgren-Åkerlund.

"There is currently no effective treatment for ARDS. It is therefore encouraging to see the promising results with Xintela's stem cells in a model that is clinically similar to the life-threatening lung complication in ARDS patients. The results show that XSTEM-ARDS has the potential to improve the severe condition in ARDS patients, which can shorten intensive care time and reduce mortality", says Professor Sandra Lindstedt.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 26th of October, 2020.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Nerladdningsbara filer

Xintela intends to carry out a directed share issue through an accelerated book building procedure

Lund, 2021-06-16

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW.

INSIDE INFORMATION: Xintela AB (publ) ("Xintela" or the "Company") hereby announces the Company's intention to carry out a new share issue, with deviation from the shareholders' preferential rights of approximately SEK 25 million, with an option to upsize the new share issue, through an accelerated bookbuilding procedure (the "Directed Issue"). The purpose of the Directed Issue is to finance the start of a clinical phase I/IIa study for stem cell treatment of knee osteoarthritis and within Oncology continue preclinical studies of the Company's targeted antibodies for the treatment of glioblastoma and triple negative breast cancer. The Directed Issue is intended to be carried out based on the authorization from the Annual General Meeting on 7 May 2021. The Directed Issue will be offered to professional investors. The Company has mandated Vator Securities to investigate the conditions for carrying out the Directed Issue.


Xintela avser att genomföra en riktad nyemission av aktier genom ett accelererat bookbuilding-förfarande

Lund, 2021-06-16

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER.

INSIDERINFORMATION: Xintela AB (publ) ("Xintela" eller "Bolaget") offentliggör härmed Bolagets avsikt att genomföra en nyemission, med avvikelse från aktieägarnas företrädesrätt, om cirka 25 MSEK, med möjlighet att utöka nyemissionen, genom ett accelererat bookbuilding-förfarande (den "Riktade Emissionen"). Syftet med den Riktade Emissionen är att finansiera start av en klinisk fas I/IIa studie för stamcellsbehandling av knäartros och inom Onkologi fortsätta prekliniska studier av Bolagets riktade antikroppar för behandling av glioblastom och trippelnegativ bröstcancer. Den Riktade Emissionen avses att genomföras med stöd av bemyndigande från årsstämman den 7 maj 2021. Den Riktade Emissionen kommer att erbjudas till professionella investerare. Bolaget har uppdragit åt Vator Securities att utreda förutsättningarna för att genomföra den Riktade Emissionen.


Xintela offentliggör delårsrapport för första kvartalet 2021

Sammanfattning av kvartalsrapporten


Xintelas GMP-anläggning erhåller tillstånd att producera cellterapiprodukter

Xintela meddelar idag att bolaget har erhållit tillstånd från Läkemedelsverket att producera cellterapiprodukter, så kallade avancerade terapiläkemedel (ATMPs), i den egna GMP-anläggningen.


Xintela's GMP facility approved for manufacturing of cell therapy products

Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility.


Xintela utvecklar stamcellsbehandling för svårläkta sår

Xintela tillkännager idag att bolaget ska utveckla sin stamcellsprodukt XSTEM® för behandling av svårläkta (kroniska) sår. I samarbete med Brännskadecentrum vid Universitetssjukhuset i Linköping har Xintela i en preklinisk sårmodell visat utmärkt sårläkningsförmåga med XSTEM och planerar nu för en klinisk studie på patienter med svårläkta sår.


Xintela to develop stem cell therapy for difficult-to-heal wounds

Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM has excellent wound healing capability in a preclinical model and is now planning for a clinical trial on patients with difficult-to-heal wounds.


Xintelas stamcellsprodukt XSTEM reparerar skadat ledbrosk i preklinisk modell

Xintela meddelar att bolagets stamcellsprodukt XSTEM® kan återbilda brosk i en preklinisk djurmodell. Studien, som är ett forskningssamarbete med Köpenhamns universitet och som syftar till att öka kunskapen om XSTEMs verkningsmekanismer, bekräftar XSTEMs stora potential i behandling av artros.


Xintela's stem cell product XSTEM repairs cartilage damage in preclinical model

Xintela announces that the company's stem cell product XSTEM® regenerates cartilage in a preclinical animal model. The study, a research collaboration between Xintela and the University of Copenhagen, designed to increase the understanding of XSTEM's mechanisms of action, confirms XSTEM's potential as a treatment for osteoarthritis.


Kommuniké från Xintelas årsstämma 2021

Lund, Sverige, 7 maj 2021 - Idag hölls årsstämma i Xintela AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.


Targinta rekryterar Per Norlén som VD

Lund, Sverige, den 4 maj 2021 - Xintela meddelar idag att Per Norlén har rekryterats som VD för Xintelas helägda dotterbolag Targinta inom onkologi. Han tillträder 1 september 2021. Per Norlén kommer även ha rollen som Xintelas Chief Medical Officer (CMO/Medicinsk Chef) från 1 juli 2021. Rekryteringen är ett viktigt steg i processen med att knoppa av Targinta som ett fristående bolag.


Targinta recruits Per Norlén as CEO

Lund, Sweden, May 4, 2021 - Xintela announces today that Per Norlén has been recruited as CEO of Xintela's wholly owned oncology subsidiary Targinta. He will start on 1 September 2021. Per Norlén will also have the role of Xintela's Chief Medical Officer (CMO) from 1 July 2021. The recruitment is an important step in the process of spinning out Targinta as an independent company.


Xintela offentliggör årsredovisning för 2020

Lund, Sverige, 16 april 2021 - Xintela AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2020. Årsredovisningen finns tillgänglig på bolagets hemsida www.xintela.se samt via bifogad PDF.


Inspektion av Xintelas GMP-verksamhet för tillverkningstillstånd genomförd

Lund, Sverige, den 12 april 2021 - Xintela meddelar idag att Läkemedelsverket har genomfört en inspektion för tillstånd att producera cellterapiprodukter, så kallade avancerade terapiläkemedel (ATMPs), för kliniska studier.


Xintela GMP inspection for manufacturing license completed

Lund, Sweden, 12 April 2021 - Xintela announces today completion of the inspection by the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
SE-102 45 Stockholm, Sweden

08-692 21 90

Om beQuoted